Investment Thesis
Prothena faces severe fundamental deterioration with 31.5% revenue decline and near-complete earnings collapse (99.6% YoY), indicating critical business model failure in its pharmaceutical operations likely from pipeline shortfalls or product losses. While the fortress balance sheet ($329.5M cash, zero debt) delays insolvency, absent credible turnaround evidence or pipeline catalysts, the company will face accelerating shareholder value destruction.
Strengths
- Fortress balance sheet with $329.5M cash and zero debt provides 2+ year runway for turnaround attempts
- Positive free cash flow of $28.8M despite revenue collapse demonstrates operational resilience
- Operating margin of 58.8% suggests core profitable business segments remain viable
Risks
- Catastrophic 31.5% revenue decline indicates loss of major products, patents, or market exclusivity in pharmaceutical company
- Net income collapse of 99.6% represents business model deterioration, not temporary cyclical weakness
- Elevated insider Form 4 activity (8 filings) suggests management uncertainty or credibility issues regarding turnaround path
- Continued revenue erosion will eventually exceed cash burn capacity despite current balance sheet strength
- As biotech company, pipeline risk is existential; no visible evidence of value-accretive assets or clinical success
Key Metrics to Watch
- Quarterly revenue trends and YoY rate of decline stabilization
- Clinical trial progress and regulatory approvals for pipeline programs
- Operating cash flow sustainability and cash burn rate as percentage of reserves
- Management changes, strategic partnerships, or capital deployment announcements
- Cash runway estimate based on current burn rate
Financial Metrics
Revenue
51.1M
Net Income
32.7M
EPS (Diluted)
$0.60
Free Cash Flow
28.8M
Total Assets
349.9M
Cash
329.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
58.8%
Net Margin
64.1%
ROE
10.5%
ROA
9.4%
FCF Margin
56.3%
Balance Sheet & Liquidity
Current Ratio
10.43x
Quick Ratio
10.43x
Debt/Equity
0.00x
Debt/Assets
10.7%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T12:37:40.060462 |
Data as of: 2026-03-31 |
Powered by Claude AI